|
|
| Countries covered: United States Push toward Zero-Risk Blood Supply Drives Market Adoption The growing patient demand for a zero-risk blood supply is driving enormous investment into the development of pathogen reduction solutions by both small biotechnology firms as well as large medical device manufacturers. Promising data related to the efficacy and safety levels of pathogen inactivation systems emerging from both research labs and clinical settings are likely to provide an impetus for improved market penetration. The development of technologies capable of killing a broad range of pathogens without causing damage to blood products is also expected to encourage market expansion. This Frost & Sullivan research examines the U.S. Pathogen Reduction Markets and includes world forecasts. It focuses on broadly applicable second-generation technologies linked to the red blood cell, plasma, platelets, and biologics manufacturing sub-segments. The study also discusses the prevailing market challenges and provides strategic recommendations to overcome them. Immense, Untapped Potential Exists in Pathogen Reduction Market Even though technologies are currently in development, the pathogen reduction market is essentially devoid of competition. Older technologies, such as solvent/detergent plasma, were regarded as being unsafe and did not have broad applicability, while newer testing technologies do not significantly decrease the window of time between the initial infection and the point at which a pathogen can be detected. "Thus, blood banks eagerly anticipate a safe technology that will easily integrate into their processing systems, and reduce the risk of transfusion-related infections virtually to zero," says the analyst. Market success will be determined by the ability to offer cost-effective technologies with a broad kill range, strong safety profile, and ease of use. The facility to influence buyer decision-making processes coupled with first-mover advantage will also be critical to gaining a competitive edge. Demonstrated Safety and Efficacy of Technologies Key to Enhanced Uptake Commercialization is likely to suffer a setback if the number of cases of infection following the installation of pathogen reduction technologies equals the number of cases prior to installation. In such a scenario, there will be no motivation to pay a premium for technologies that fail to increase the safety of blood. Similarly, adverse effects resulting from toxicity or damaged blood products are certain to hamper commercialization. Therefore, demonstrating the safety and efficacy of pathogen reduction technologies will be crucial to boosting deployment. "Although only one pathogen reduction system has been approved for marketing in Europe, incoming technologies, which are currently in trials, have thus far shown outstanding data regarding safety and efficacy, "states the analyst." This promising data, should it hold as trials continue, is likely to underline rapid and broad market adoption." |
More United States Blood Reports
Therapeutic Apheresis by
Global Industry Analysts
This report analyzes the US market for Therapeutic Apheresis in US$ Thousand by the following procedures: Photopheresis, Plasmapheresis, Erythrocytapheresis, Plateletpheresis, Leukapheresis, and Lipidpheresis. The ...
Therapeutic Apheresis - A US Market Review by
BizAcumen, Inc.
Although therapeutic apheresis is a potential market, soaring treatment costs and lack of awareness debilitate its growth. However, with increasing alliances and agreements, research for ...
Medical Membrane Devices: Markets and Technologies by
BCC Research
This Report:
Provides a U.S. market review for medical membrane devices and technologies
Offers the current U.S. market status for medical membrane devices ...
US Markets for Clot Management Devices 2009 by
Millennium Research Group
The clot management device market will be predominantly driven by product innovations that result in more efficient treatment times, reduced complications, and better patient outcomes ...
Diagnostics and Therapeutics for Genetic Diseases by
BCC Research
REPORT HIGHLIGHTS
The U.S. market for therapeutics and diagnostics for genetic diseases reached $4.8 billion in 2005 and is expected to grow at an ...
See all reports like this >>
More United States Reports
e-Discovery Software Publishing in the US - Industry Market Research Report by
IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...
D&B Country RiskLine Report: The United States of America by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by
Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>
